United States-based pharmaceutical company AbbVie (NYSE: ABBV announced on Friday that it has received approval from the US Food and Drug Administration (FDA) for its EMBLAVEO (aztreonam and avibactam), as the first and only fixed-dose, intravenous, monobactam/beta-lactamase inhibitor combination antibiotic.

AbbVie said that EMBLAVEO is approved in combination with metronidazole, for patients 18 years and older who have limited or no alternative options for the treatment of complicated intra-abdominal infections (cIAI), including those caused by the following susceptible Gram-negative microorganisms: Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae complex, Citrobacter freundii complex and Serratia marcescens.

EMBLAVEO is approved for this indication based on limited clinical safety and efficacy data. It will be available for commercial use in the United States during the third quarter of 2025.